vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and FORRESTER RESEARCH, INC. (FORR). Click either name above to swap in a different company.
FORRESTER RESEARCH, INC. is the larger business by last-quarter revenue ($101.1M vs $62.1M, roughly 1.6× Cytek Biosciences, Inc.). FORRESTER RESEARCH, INC. runs the higher net margin — -33.5% vs -70.9%, a 37.4% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs -6.5%). Cytek Biosciences, Inc. produced more free cash flow last quarter ($-1.8M vs $-4.3M). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 0.5%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
Forrester Research, Inc. is a research and advisory firm working in research, consulting and events. Forrester’s clients include large global business, technology and consumer enterprises. The firm is headquartered in Cambridge, MA.
CTKB vs FORR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $101.1M |
| Net Profit | $-44.1M | $-33.9M |
| Gross Margin | 52.9% | 56.7% |
| Operating Margin | -9.0% | -36.6% |
| Net Margin | -70.9% | -33.5% |
| Revenue YoY | 8.1% | -6.5% |
| Net Profit YoY | -557.1% | -7941.4% |
| EPS (diluted) | — | $-1.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | $101.1M | ||
| Q3 25 | $52.3M | $94.3M | ||
| Q2 25 | $45.6M | $111.7M | ||
| Q1 25 | $41.5M | $89.9M | ||
| Q4 24 | $57.5M | $108.0M | ||
| Q3 24 | $51.5M | $102.5M | ||
| Q2 24 | $46.6M | $121.8M | ||
| Q1 24 | $44.9M | $100.1M |
| Q4 25 | $-44.1M | $-33.9M | ||
| Q3 25 | $-5.5M | $-2.1M | ||
| Q2 25 | $-5.6M | $3.9M | ||
| Q1 25 | $-11.4M | $-87.3M | ||
| Q4 24 | $9.6M | $432.0K | ||
| Q3 24 | $941.0K | $-5.8M | ||
| Q2 24 | $-10.4M | $6.3M | ||
| Q1 24 | $-6.2M | $-6.7M |
| Q4 25 | 52.9% | 56.7% | ||
| Q3 25 | 52.7% | 60.0% | ||
| Q2 25 | 52.3% | 55.5% | ||
| Q1 25 | 48.6% | 55.9% | ||
| Q4 24 | 58.5% | 58.8% | ||
| Q3 24 | 56.3% | 60.5% | ||
| Q2 24 | 54.6% | 57.3% | ||
| Q1 24 | 51.3% | 54.9% |
| Q4 25 | -9.0% | -36.6% | ||
| Q3 25 | -17.6% | 4.7% | ||
| Q2 25 | -23.3% | 6.2% | ||
| Q1 25 | -36.1% | -97.5% | ||
| Q4 24 | 5.2% | -0.5% | ||
| Q3 24 | -8.2% | -0.7% | ||
| Q2 24 | -18.3% | 9.3% | ||
| Q1 24 | -23.9% | -9.3% |
| Q4 25 | -70.9% | -33.5% | ||
| Q3 25 | -10.5% | -2.3% | ||
| Q2 25 | -12.2% | 3.5% | ||
| Q1 25 | -27.5% | -97.1% | ||
| Q4 24 | 16.8% | 0.4% | ||
| Q3 24 | 1.8% | -5.7% | ||
| Q2 24 | -22.4% | 5.2% | ||
| Q1 24 | -13.8% | -6.7% |
| Q4 25 | — | $-1.75 | ||
| Q3 25 | — | $-0.11 | ||
| Q2 25 | — | $0.20 | ||
| Q1 25 | — | $-4.62 | ||
| Q4 24 | — | $0.02 | ||
| Q3 24 | — | $-0.30 | ||
| Q2 24 | — | $0.33 | ||
| Q1 24 | — | $-0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | $63.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $341.7M | $126.5M |
| Total Assets | $461.5M | $404.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.9M | $63.3M | ||
| Q3 25 | $93.3M | $65.1M | ||
| Q2 25 | $75.5M | $67.8M | ||
| Q1 25 | $95.3M | $75.6M | ||
| Q4 24 | $98.7M | $56.1M | ||
| Q3 24 | $162.3M | $62.8M | ||
| Q2 24 | $177.9M | $58.9M | ||
| Q1 24 | $168.8M | $61.4M |
| Q4 25 | $341.7M | $126.5M | ||
| Q3 25 | $378.6M | $157.7M | ||
| Q2 25 | $377.6M | $159.5M | ||
| Q1 25 | $379.6M | $147.4M | ||
| Q4 24 | $395.7M | $229.5M | ||
| Q3 24 | $385.5M | $234.3M | ||
| Q2 24 | $389.1M | $237.1M | ||
| Q1 24 | $392.6M | $230.9M |
| Q4 25 | $461.5M | $404.0M | ||
| Q3 25 | $494.9M | $414.2M | ||
| Q2 25 | $493.3M | $436.0M | ||
| Q1 25 | $482.6M | $439.8M | ||
| Q4 24 | $499.5M | $503.9M | ||
| Q3 24 | $491.2M | $505.3M | ||
| Q2 24 | $483.7M | $524.2M | ||
| Q1 24 | $492.1M | $555.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | $-3.2M |
| Free Cash FlowOCF − Capex | $-1.8M | $-4.3M |
| FCF MarginFCF / Revenue | -2.9% | -4.2% |
| Capex IntensityCapex / Revenue | 1.6% | 1.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | $18.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-771.0K | $-3.2M | ||
| Q3 25 | $-3.9M | $1.2M | ||
| Q2 25 | $108.0K | $-3.6M | ||
| Q1 25 | $-125.0K | $26.7M | ||
| Q4 24 | $2.0M | $-1.8M | ||
| Q3 24 | $13.2M | $264.0K | ||
| Q2 24 | $6.2M | $-2.9M | ||
| Q1 24 | $4.0M | $611.0K |
| Q4 25 | $-1.8M | $-4.3M | ||
| Q3 25 | $-4.6M | $524.0K | ||
| Q2 25 | $-1.5M | $-4.2M | ||
| Q1 25 | $-974.0K | $26.1M | ||
| Q4 24 | $1.1M | $-2.5M | ||
| Q3 24 | $12.2M | $-223.0K | ||
| Q2 24 | $5.2M | $-3.7M | ||
| Q1 24 | $3.4M | $-815.0K |
| Q4 25 | -2.9% | -4.2% | ||
| Q3 25 | -8.7% | 0.6% | ||
| Q2 25 | -3.2% | -3.8% | ||
| Q1 25 | -2.3% | 29.0% | ||
| Q4 24 | 1.9% | -2.3% | ||
| Q3 24 | 23.7% | -0.2% | ||
| Q2 24 | 11.0% | -3.1% | ||
| Q1 24 | 7.6% | -0.8% |
| Q4 25 | 1.6% | 1.1% | ||
| Q3 25 | 1.3% | 0.7% | ||
| Q2 25 | 3.5% | 0.5% | ||
| Q1 25 | 2.0% | 0.7% | ||
| Q4 24 | 1.6% | 0.6% | ||
| Q3 24 | 2.0% | 0.5% | ||
| Q2 24 | 2.3% | 0.7% | ||
| Q1 24 | 1.3% | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.93× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | -4.24× | ||
| Q3 24 | 14.05× | — | ||
| Q2 24 | — | -0.46× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
